Avenue Therapeutics, Inc.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Alexandra MacLean
- Full Time Employees
- 2
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 1140 Avenue of the America New York City NY United States of America 10036
- IPO Date
- Jun 27, 2017
- CIK
- 0001644963
- Website
- avenuetx.com
- Similar Companies
- Business
- Avenue Therapeutics, Inc. (OTC: ATXI) is a specialty pharmaceutical company whose primary business centers on the development and commercialization of innovative therapies targeting neurologic diseases and acute pain management; its core pipeline includes intravenous (IV) tramadol, in Phase 3 clinical development for moderate-to-severe postoperative pain in medically supervised settings; AJ201 (also known as AT-201), in Phase 1b/2a trials for spinal and bulbar muscular atrophy (SBMA, or Kennedy's Disease), a rare neuromuscular disorder, designed to degrade mutant androgen receptor proteins and activate cellular stress pathways; and, prior to its recent divestiture, BAER-101 (now AXS-17), an oral small-molecule selective GABA-A alpha2/3 receptor positive allosteric modulator originally licensed from AstraZeneca for central nervous system disorders including epilepsy and panic disorders, tested in over 700 patients with a favorable safety profile. The company, founded in 2015 as a subsidiary of Fortress Biotech, Inc. (Nasdaq: FBIO), maintains headquarters at 1111 Kane Concourse, Suite 301, Bay Harbor Islands, Florida, and operates principally in the United States with a lean team focused on late-stage assets in the biotechnology and pharmaceutical sectors, serving patients with high unmet needs in neurology and analgesia through rigorous clinical advancement and strategic partnerships. In a major recent development announced November 6, 2025, Avenue's majority-owned subsidiary Baergic Bio, Inc., holder of global rights to BAER-101, was acquired by Axsome Therapeutics, Inc. (Nasdaq: AXSM), providing an upfront payment of $0.3 million (net of expenses) and up to approximately $82 million in milestones plus mid-to-high single-digit royalties on net sales, with Avenue retaining about 74% of future proceeds as Axsome advances the asset in epilepsy based on preclinical data.
Comparing Avenue Therapeutics (NASDAQ:ATXI) & Graybug Vision (NASDAQ:GRAY)
Avenue Therapeutics Enters into Exclusive Worldwide License Agreement for ATX-04 for the Treatment of Pompe Disease
Reviewing Avenue Therapeutics (NASDAQ:ATXI) and Endonovo Therapeutics (OTCMKTS:ENDVD)
Contrasting ObsEva (NASDAQ:OBSV) & Avenue Therapeutics (NASDAQ:ATXI)
NexImmune (NASDAQ:NEXI) versus Avenue Therapeutics (NASDAQ:ATXI) Head-To-Head Comparison
Avenue Therapeutics Announces Acquisition of Subsidiary Baergic Bio by Axsome Therapeutics
Avenue Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights
Avenue Therapeutics to Participate in Maxim Group's 2024 Healthcare Virtual Summit
Avenue Therapeutics to Participate in Upcoming Investor Conferences
Avenue Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights
Avenue Therapeutics to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
Avenue Therapeutics Announces Last Patient Last Visit in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)
Avenue Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross Proceeds
Avenue Therapeutics Announces Reverse Stock Split
Avenue Therapeutics to Host Virtual Key Opinion Leader (KOL) Event on April 4, 2024
Avenue Therapeutics Reports Full Year 2023 Financial Results and Recent Corporate Highlights
Avenue Therapeutics Receives Positive Listing Determination from Nasdaq
Avenue Therapeutics to Present BAER-101 Preclinical Data at American Society for Experimental Neurotherapeutics (ASENT) 2024 Annual Meeting
Avenue Therapeutics Announces Publication in Drug Development Research Highlighting First-In-Class Preclinical Data of BAER-101 in a Translational Model of Absence Epilepsy